دورية أكاديمية
Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis.
| العنوان: | Serum pro-inflammatory biomarkers associated with improvement in quality of life in pulmonary tuberculosis. |
|---|---|
| المؤلفون: | Carreto-Binaghi LE; Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., Sartillo-Mendoza LG; Departamento de Investigación en Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico.; Facultad de Medicina, Benemérita Universidad Autónoma de Puebla (BUAP), Puebla, Mexico.; Becario de la Dirección General de Calidad y Educación en Salud, Secretaría de Salud, Mexico, Mexico., Muñoz-Torrico M; Clínica de Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., Guzmán-Beltrán S; Departamento de Investigación en Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., Carranza C; Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., Torres M; Laboratorio de Inmunobiología de la Tuberculosis, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., González Y; Departamento de Investigación en Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico., Juárez E; Departamento de Investigación en Microbiología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico, Mexico. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Sep 11; Vol. 14, pp. 1241121. Date of Electronic Publication: 2023 Sep 11 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Tuberculosis, Pulmonary*/drug therapy , Latent Tuberculosis*, Humans ; Quality of Life ; Antioxidants ; Leukotriene B4 ; Cognition |
| مستخلص: | Introduction: Pulmonary dysfunction is an underestimated complication in tuberculosis (TB) infection, affecting quality of life (QoL). Although respiratory function tests objectively reflect lung disturbances in a specific moment, predictors of illness severity at the time of diagnosis are still lacking. Methods: We measured serum pro-inflammatory cytokines (TNF-α and IL-8), eicosanoids (PGE2, LTB4, RvD1, Mar1, and LXA4), a marker of tissue damage (cell-free nucleosomes), and indicators of redox status (malonaldehyde, 8-isoprostane, total oxidants, and antioxidants), as well as a score of radiological abnormalities (SRA) and a QoL questionnaire, in 25 patients with pulmonary TB at the time of diagnosis (t0) and two months after the initiation of treatment (t2). Results: We found higher antioxidant levels in the patients with the worst QoL at t0, and all the indicators of the prooxidant state were significantly reduced at t2, while the total antioxidant levels increased. LTB4, a pro-inflammatory eicosanoid, was diminished at t2, while all the pro-resolutory lipids decreased substantially. Significant correlations between the SRA and the QoL scores were observed, the latter showing a substantial reduction at t2, ranking it as a reliable tool for monitoring disease evolution during TB treatment. Discussion: These results suggest that evaluating a combination of these markers might be a valuable predictor of QoL improvement and a treatment response indicator; in particular, the oxidation metabolites and eicosanoid ratios could also be proposed as a future target for adjuvant therapies to reduce inflammation-associated lung injury in TB disease. Competing Interests: The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Carreto-Binaghi, Sartillo-Mendoza, Muñoz-Torrico, Guzmán-Beltrán, Carranza, Torres, González and Juárez.) |
| References: | Chin Med J (Engl). 2017 Mar 20;130(6):730-736. (PMID: 28303858) J Infect Dis. 2008 Nov 15;198(10):1514-9. (PMID: 18811584) Front Pharmacol. 2017 Dec 18;8:919. (PMID: 29326591) Medicina (Kaunas). 2017;53(6):386-393. (PMID: 29496377) Mol Imaging Biol. 2019 Feb;21(1):19-24. (PMID: 29845428) Tuberculosis (Edinb). 2012 Jul;92(4):293-300. (PMID: 22503371) PLoS One. 2013 Nov 01;8(11):e78926. (PMID: 24223865) Nat Immunol. 2010 Aug;11(8):751-8. (PMID: 20622882) Int J Tuberc Lung Dis. 2017 Mar 1;21(3):278-285. (PMID: 28225338) Antioxid Redox Signal. 2021 Feb 20;34(6):471-485. (PMID: 32559410) Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. (PMID: 31613151) PLoS One. 2013 Apr 18;8(4):e61002. (PMID: 23637781) J Clin Microbiol. 2022 Feb 16;60(2):e0185921. (PMID: 34911364) Front Cell Infect Microbiol. 2019 Oct 01;9:335. (PMID: 31632923) Int J Tuberc Lung Dis. 2019 Apr 1;23(4):450-457. (PMID: 31064624) J Allergy Clin Immunol. 2018 Jan;141(1):117-127. (PMID: 28506850) Int J Lab Hematol. 2018 Aug;40(4):392-399. (PMID: 29520957) PLoS One. 2013 Nov 29;8(11):e80302. (PMID: 24312209) Sci Rep. 2020 Nov 11;10(1):19527. (PMID: 33177551) Tuberculosis (Edinb). 2015 Dec;95(6):659-663. (PMID: 26386744) Front Immunol. 2019 Feb 05;10:47. (PMID: 30804927) PLoS One. 2018 Mar 15;13(3):e0192664. (PMID: 29543810) Dermatol Ther. 2020 Nov;33(6):e14460. (PMID: 33107160) ERJ Open Res. 2020 Aug 31;6(3):. (PMID: 32904577) J Infect Dis. 2012 Dec 15;206(12):1803-5. (PMID: 23033145) Chest. 2007 Nov;132(5):1591-8. (PMID: 17890471) Int J Infect Dis. 2019 May;82:66-72. (PMID: 30844519) Chest. 2003 Jun;123(6):1988-95. (PMID: 12796179) PLoS Genet. 2023 Mar 27;19(3):e1010387. (PMID: 36972313) Front Immunol. 2020 Nov 12;11:579849. (PMID: 33304347) Am J Respir Crit Care Med. 2006 Jan 15;173(2):238-45. (PMID: 16210664) J Clin Tuberc Other Mycobact Dis. 2022 Nov 29;29:100343. (PMID: 36478777) Chest. 2016 Sep;150(3):747-8. (PMID: 27613980) Mucosal Immunol. 2011 May;4(3):252-60. (PMID: 21430655) Cytokine X. 2020 May 13;2(2):100028. (PMID: 33604556) PLoS One. 2011;6(10):e26254. (PMID: 22028843) Antioxidants (Basel). 2021 Oct 05;10(10):. (PMID: 34679707) |
| فهرسة مساهمة: | Keywords: eicosanoids; inflammation-associated lung injury; quality of life; redox indicators; tuberculosis |
| المشرفين على المادة: | 0 (Antioxidants) 1HGW4DR56D (Leukotriene B4) |
| تواريخ الأحداث: | Date Created: 20230927 Date Completed: 20230928 Latest Revision: 20230929 |
| رمز التحديث: | 20231215 |
| مُعرف محوري في PubMed: | PMC10518397 |
| DOI: | 10.3389/fimmu.2023.1241121 |
| PMID: | 37753080 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1241121 |